When was Protai founded?

Protai was founded in 2021 and raised its 1st funding round 1 year after it was founded.

Where is Protai located?

Protai is headquartered in Tel Aviv, Israel.

How many employees does Protai have?

As of Sep 30, 2026, the latest employee count at Protai is 29.

Is Protai a funded company?

Protai is a funded company, having raised a total of $20M across 2 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Jan 05, 2022.

When was the latest funding round of Protai?

Protai's latest funding was a $***** Seed round on Mar 15, 2023, with participation from 3 investors. Its primary sector is Life Sciences Tech. In Israel, the Life Sciences Tech sector has seen $45M in funding in 2026 to date.

Where does Protai rank among its competitors?

Protai ranks 25th amongst 70 active competitors, of which 40 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Converge, which secured $2.5M in Jun, 2026.

Who are the top competitors of Protai?

Protai's top competitors include Generate Biomedicines, Cradle and Profluent Bio. Among them, Converge secured the most recent funding round in June, 2026.

Protai - 2026 Company Profile, Funding & Competitors

Company Details

Website: protai.bio
Social

Key Metrics

Founded Year

2021

Location

Tel Aviv, Israel

Stage

Seed

Total Funding

$20M in 2 rounds

Latest Funding Round

Seed, Mar 15, 2023, $*****

Investors

Pitango & 2 more

Ranked

25^th among 70 active competitors

Employee Count

29 as on Sep 30, 2026

Similar Companies

Generate Biomedicines & 74 more

View Protai's full profile

Protai has raised a total funding of $20M over 2 rounds. Its first funding round was on Jan 05, 2022. Its latest funding round was a Seed round on Mar 15, 2023 for $*****. 3 investors participated in its latest round. Protai has 3 institutional investors.

Here is the list of recent funding rounds of Protai:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 15, 2023	4045370	Seed	1364398	6599637	6907759	1106100
Jan 05, 2022	6578129	Seed	3009932	5150637	Grove Ventures & 1 more	6177870

Access funding benchmarks and valuations. Sign up today!

View details of Protai's funding rounds and investors

Protai's employee count trend

Protai has 29 employees as of Sep 26. Here is Protai's employee count trend over the years:

Uncover Protai's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Protai include Generate Biomedicines, Cradle and Profluent Bio. Here is the list of Top 10 competitors of Protai, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Generate Biomedicines 2018, Somerville (United States), Public	Developer of a platform for generating novel protein-based therapeutic modalities	$693M	Pictet Group, NVentures & 14 others	67/100
2nd	Cradle 2021, Zurich (Switzerland), Series B	Provider of chemoproteomics solutions for protein design and development	$103M	Index Ventures, Kindred Capital & 7 others	67/100
3rd	Profluent Bio 2022, Berkeley (United States), Series B	Provider of an artificial intelligence-based protein design platform	$150M	Spark Capital, Altimeter Capital & 6 others	66/100
4th	Nimbus Therapeutics 2009, Cambridge (United States), Series F	Developer of targeted therapeutics for cancer, metabolic and inflammatory diseases	$637M	BVF Partners, Atlas Venture & 20 others	64/100
5th	EvolutionaryScale 2023, New York City (United States), Seed	Provider of an AI models for protein design	$142M	Lux Capital, Amazon & 3 others	64/100
6th	Eikon 2019, Millbrae (United States), Public	Protein tracking and measuring tool for drug discovery	$1.16B	The Column Group, T. Rowe Price & 23 others	64/100
7th	Frontier Medicines 2018, San Francisco (United States), Series C	Developer of a bioinformatics platform for drug development and chemoproteomics	$236M	Deerfield, RA Capital Management & 11 others	58/100
8th	AI Proteins 2021, Boston (United States), Series A	Developer of de novo designed miniproteins for therapeutic applications	$59.7M	Mission BioCapital, Sante & 4 others	58/100
9th	Seismic 2019, Watertown (United States), Series B	AI-assisted platform for drug discovery and development	$247M	Lightspeed Venture Partners, Bessemer Venture Partners ... & 12 others	58/100
10th	Converge 2024, Wilmington (United States), Series A	Developer of GenAI computational tools for drug discovery and manufacturing	$30.5M	Bessemer Venture Partners, TLV Partners & 3 others	56/100
25th	Protai 2021, Tel Aviv (Israel), Seed	Provider of AI-enabled platform for proteomics based drug discovery and development	$20M	Pitango, Grove Ventures & 1 others	43/100